Ozempic(R) Consistently Reduced the Risk of Major Cardiovascul...
MUNICH, Aug. 26, 2018 /PRNewswire-AsiaNet/-- Ozempic(R) Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at BaselineOzempic(R) (semaglutide) consistently reduced the risk of the composite outcome...
Read more https://view-release/?pr-id=74893